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Background: p53 (encoded by TP53) is involved in DNA damage repair, cell cycle regulation, apoptosis, aging and
cellular senescence. TP53 is mutated in around 50% of human cancers. Nevertheless, the consequences of p53
inactivation in colon cancer outcome remain unclear. Recently, a new role of p53 together with CSNK1A1 in colon
cancer invasiveness has been described in mice.
Methods: By combining data on different levels of p53 inactivation, we aimed to predict p53 functionality and to
determine its effects on colon cancer outcome. Moreover, survival effects of CSNK1A1 together with p53 were also
studied.
Eighty-three formalin fixed paraffin embedded colon tumors were enriched for tumor cells using flow sorting, the
extracted DNA was used in a custom SNP array to determine chr17p13-11 allelic state; p53 immunostaining, TP53
exons 5, 6, 7 and 8 mutations were determined in combination with mRNA expression analysis on frozen tissue.
Results: Patients with a predicted functional p53 had a better prognosis than patients with non functional p53
(Log Rank p=0.009). Expression of CSNK1A1 modified p53 survival effects. Patients with low CSNK1A1 expression and
non-functional p53 had a very poor survival both in the univariate (Log Rank p<0.001) and in the multivariate
survival analysis (HR=4.74 95% CI 1.45 – 15.3 p=0.009).
Conclusion: The combination of mutational, genomic, protein and downstream transcriptional activity data
predicted p53 functionality which is shown to have a prognostic effect on colon cancer patients. This effect was
specifically modified by CSKN1A1 expression.
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During colon carcinogenesis cells accumulate several gen-
etic and genomic aberrations that lead to uncontrolled
proliferation and tumor formation [1]. A major event in
the adenoma to carcinoma transition is TP53 inactivation.
p53 plays a crucial role in maintaining genome stability
and integrity. Upon DNA damage, the activation of p53
leads to cell cycle arrest enabling the cells to repair the
damaged DNA. On the other hand, when the damage is
too extensive to be repaired p53 activation can also drive
the cell towards apoptosis or senescence [2]. Recently, p53
has also been implicated in tumor invasiveness [3]. In* Correspondence: j.morreau@lumc.nl
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distribution, and reproduction in any mediummice, the inactivation of casein kinase 1 alpha (Csnk1a1)
promotes the cytoplasmatic/nuclear accumulation of β
catenin which stimulates the transcription of Wnt signal-
ing target genes. The combined inactivation of p53 and
Csnk1a1 rapidly leads to tumor invasiveness in the colon
of these mice.
Inactivation of TP53 is one of the most frequent
events in human cancer [4]. Among others, TP53 can
be inactivated by “loss of function” mutations in one
allele and deletion of the remaining wild type allele or
by dominant negative mutations that are able to in-
activate also the wild type protein transcribed by the
second unaffected allele. Either way, when p53 func-
tion is jeopardized, genomic instability and uncon-
trolled cell proliferation are facilitated.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sion and prognosis has been widely studied but remains
elusive notwithstanding the amount of reports address-
ing this subject [5-17]. Chromosomal instability (CIN)
is a known prognostic factor in colon cancer [18]. Al-
though p53 inactivation has been frequently associated
with CIN, not all tumors with CIN carry an inactive
p53 and vice versa [19]. More complexity is added by
the recent demonstration that TP53 can behave as a
haploinsufficient tumor suppressor gene. Using mouse
models, Ventakachalam and coworkers demonstrated
that mice carrying one functional p53 allele developed
tumors but they showed however a milder phenotype
than mice that lost both alleles [20]. Moreover, several
reports described the TP53 gene dosage effect on ex-
pression of target genes [21,22].
Recent developments in genomic copy number ana-
lysis have shown to more accurately study the measure
of chromosomal structural and numeric aberrations
[23]. The development of the lesser allele intensity ratio
(LAIR) algorithm that integrates the DNA index in the
analysis of copy number data gives a real measure of the
chromosomal alterations and allows the study of gene
dosage effects in tumors.
Given the complexity of the p53 network, the sev-
eral ways of p53 inactivation, and the recently de-
scribed role of p53 in cancer invasiveness in mice, we
studied in detail different levels of p53 inactivation in
human colon cancer taking into account the allelic
state of the locus on the short arm of chromosome
17, gene mutation state, protein expression levels,
downstream target gene expression and determine the
prognostic impact in colon cancer patients. Moreover,
interactions with the recently described CSNK1A1 ex-




Inclusion criteria for this study were sporadic colorectal
cancers in stage I, II and III. Stage IV patients were not
included because the disease is metastasized and there-
fore the therapy has a palliative character instead of a
curative character.
Thus, eighty-three sporadic colorectal cancer patients
diagnosed as stage I, II or III at the Leiden University
Medical Centre between 1991 and 2005 were selected
for the present study. Microsatellite instability of these
cancers had been determined for this group, as described
elsewhere [24]. The use of clinical material was approved
by the medical ethical board of the Leiden University
Medical Centre
Tumors were classified according to the WHO classifi-
cation of tumors of the digestive system [25].Methods
Determination of p53 functionality
Tissue preparation for multiparameter flow cytometry and
sorting
Tumor and stromal cells were sorted from FFPE tissue
blocks using the FACS ARIA I (BD Biosciences, San
Jose, CA, USA) based on vimentin, keratin expression
and DNA content as previously described by Corver
et al. [26,27]. DNA index (DI) defined as the ratio be-
tween the median G0/G1 keratin positive epithelial frac-
tion and the median GO/G1 vimentin stromal fraction,
was calculated using a remote link between Winlist and
ModFit (Verity Software House) for each sample. When-
ever, more than one keratin positive population was
seen, it was independently sorted. DI was categorized as
DI< 0.95; DI=0.95 – 1.05; DI=1.06 – 1.4; DI=1.41 – 1.95
and DI>1.95.
DNA was purified from sorted cells after an overnight
proteinase K digestion using the Nucleospin Tissue kit
(Macherey Nagel, Düren, Germany) following manufac-
turer’s instructions.
SNP array hybridization for allelic state determination
A custom Golden Gate genotyping panel with 384 SNPs
was designed using the Assay Design Tool (Illumina Inc.
San Diego, CA, USA). The panel contains SNPs map-
ping to the following chromosomes: 1q21-25, 8q22-24,
13q12-34, 17p13-11 (the TP53 locus), 18q12-22, 20q11-
13, all of which are associated with tumor progression in
the colorectum [28]. SNPs on chromosome 2 served as
controls. Paired samples were analysed in the Golden
Gate assay as described [29] and hybridized to Sentrix
Array Matrix with 384 bead types. SNP arrays were
analysed in the BeadarraySNP package. The data gener-
ated was analyzed with the LAIR algorithm [23] that in-
tegrates the DNA index into the analysis. Four observers
determined LAIR scores independently (AFS, WEC, GIF
and TVW). FISH validated the 3 of the 83 samples that
showed discordance (3.6%) between the observers.
We differentiated the following allelic states:
1) Retention with genotype AB; 2) Loss of heterozygos-
ity (LOH), genotype A; 3) copy neutral LOH (cnLOH),
genotype AA; 4) amplified LOH (aLOH) genotypes AAA
or AAAA etc.; 5) allelic imbalance (AI) or genotypes AAB,
AAABB etc.; 6) balanced amplification (BA), genotypes
AABB, AAABBB etc.; 7) multiclonal tumors (identified
through flow cytometry, see Figure 1a and b) [23].
FISH
To confirm the copy number results obtained with the
SNP array, FISH in nuclei obtained from FFPE material
of seven patients was performed. First, 2mm. punches
(Beecher Instruments, Silver Springs, MD, USA) of
a)
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Figure 1 a) Schematic representation of the possible allelic states according to LAIR scores b) Example of a DNA histogram of one
tumor containing two populations with different DNA indexes. Green histogram is the DNA diploid vimentin positive stromal fraction and in
red the keratin positive epithelial fraction.
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paraffin blocks. Subsequently, 50 μM slices were obtained,
deparaffinized and rehydrated. Antigen retrieval was
performed by high pressure cooking in Tris-EDTA pH=9.
After incubation for one hour at 37°C with RNAse, sam-
ples were digested with 0.5% pepsin pH=2 at 37°C for 30
minutes. The obtained nuclei were then washed and
resuspended in methanol: acetic acid in a 3 to 1 propor-
tion. Thereafter nuclei were spun onto clean glasses
and hybridization with Vysis® TP53/CEP17 FISH probe
kit (Abbot Molecular, IL, USA) was allowed overnight
at 37°C. After washing, samples were mounted with
Vectashield® mounting medium containing DAPI (Vector
Laboratories Inc., Burlingame, CA, USA) and nuclei were
evaluated under the fluorescence microscope.
Seven tumors were tested for which enough material
was available and with different allelic states of chr.17p
according to the SNP array analysis.
p53 IHC staining
Tissue microarrays (TMA) of these tumors were pre-
pared by punching three representative tumor areas
selected by a pathologist (HM) on HE stained slides
and arraying them on a recipient paraffin block
(Beecher Instruments, Silver Springs, MD, USA). Five
μM slices were then cut. Heat induced antigen re-
trieval (HIAR) was performed as described elsewhere
[28] and staining was carried out with the mouse anti-
human monoclonal antibodies directed against p53
(clone D0-7, 1:1000 dilution) (Lab Vision NeoMarkers,
Fremont, CA, USA).
p53 was scored in four different categories based on
any level of nuclear staining, like previously described[30] by an experienced pathologist (HM) and a path-
ology resident (AFS): completely negative; 1- 25% posi-
tive nuclei (indicative of a wild type state); 25-75%
positive nuclei and >75% positive nuclei. For analysis
purposes, the last two categories were fused in only one
category; more than 25% positive cells (indicative of a
mutated gene).
TP53 mutation analysis
Tumor DNA available from 40 patients was isolated from
enriched tumor areas containing at least 50% tumor cells,
as described above. Four different PCRs were performed
for amplification of exons 5, 6, 7 and 8 of the TP53
gene. Ten nanograms DNA was used for each PCR using
primers already published modified for SYBRgreen® detec-
tion [31]. Subsequently, PCR products were purified using
Qiagen’s MinElute™96 UF PCR Purification Kit (Qiagen
Sciences, Germantown, MD, USA) and reactions were se-
quenced using the MI13 forward and reverse primers.
Analysis was performed using the Mutation Surveyor 3.97®
sequence analysis and assembly software (SoftGenetics
LLC, Stage College, PA, USA).
mRNA expression arrays
Fresh frozen tissue of fifty-seven patients was available
for mRNA expression analysis. mRNA was isolated, la-
beled and hybridized to customized Agendia 44 K oligo-
nucleotide array as described elsewhere [24].
Statistical analysis
Associations between categorical variables were studied
by χ2 and Fischer exact test. Univariate survival analysis
was performed by Kaplan Meier analysis and differences
Table 1 Patients’ characteristics
























Multiple clones 14 (17)
DNA index
0.95 – 1.05 35 (46)
1.06 – 1.40 10 (13)





0 % 10 (13)
>0% - ≤25% 35 (46)
>25% 31 (41)
Median Follow up in months (range) 68.84 (2–199)
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lysis. Cox Proportional Hazard Model performed multi-
variate survival analysis. Cancer Specific Survival was
defined as the time between curative intended surgery
and death by cancer related causes [32]. Results were
considered significant when p value <0.05. All tested
were two tailed. All of the analyses mentioned above
were performed using SPSSv16 package for Windows
(Chicago, IL, USA)
Statistical analysis of the mRNA expression data
was done using the LIMMA (Linear Modelling for
Microarray Analysis) framework in Bioconductor [33].
The expression of the 35 genes reported by Yoon et al.
[22] as genes which expression is TP53 gene dosage
dependent was analyzed in relation with p53 functional
state. Furthermore, expression levels of three probes
targeting different locations in the 3’UTR of the
CSNK1A1 gene (NM_001025105.1 transcript) were inde-
pendently analyzed.
Finally, expression levels of eight genes reported by
Elyada et al. [3] as involved in murine tumor invasive-
ness were also analyzed.
Results
Patients’ description
Patients’ characteristics are shown in Table 1. Summa-
rized, 54% of the patients were female, 63% of the tu-
mors were right sided (i.e. tumors located in the colon
from the cecum until the splenic flexure) and 37% left
sided. 4% of the patients had stage I disease at diagnosis,
61% stage II and 35% stage III. Twenty-seven tumors
were MSI-H (33%), whereas 55 (67%) were MSS tumors.
Median follow up was 69 months (range 2 – 199).
At the end of the follow up, 41% of the patients were
alive, 24% of the patients had died because of cancer
related causes and 30% died because of non-cancer re-
lated causes.
Allelic state
All samples were flow cell sorted as previously described
and analyzed with a custom SNP array comprising sev-
eral chromosomal regions previously reported to be im-
plicated in colorectal cancer progression [28]. In the
present study we have focused on the allelic state of the
TP53 locus on chromosome 17p13-11 Of the 83 tumors
analyzed, 47% were classified as normal with genotype
AB, 11% as LOH (genotype A), 13% as cnLOH (geno-
type AA), 8% as aLOH (genotype AAA/AAAA) and 4%
as AI (genotype AAB/AAABB). Note also that 17% of
the patients showed multiple cancer populations by flow
cytometry (results shown in Table 1). No balanced am-
plifications were seen in the monoclonal series. FISH
analysis was used to confirm the chromosome 17 LAIR
scores for seven samples (Figure 2).Predicted p53 functionality
We predicted the functionality of p53 (hereafter called
functionality) for each sample (see Additional file 1:
Table S1) by combining data from the TP53 locus allelic
state, mutation data and protein expression levels. Over-
all, the three parameters were mostly in agreement with
each other, except for 6 out of 57 patients where there
was one discordance between mutation state, protein ex-
pression and/or allelic state. To call p53 non functional,
Sample 1 DNA index = 1.1
Sample 2 DNA index = 2.3 
a) b)
a) b)
LAIR chr 2: AB LAIR chr.17: A FISH: two centromeres and one p53 copy
LAIR chr. 2: AABB LAIR chr.17 AAAA FISH: four centromeres and four p53 copies 
Figure 2 Results of a) SNP array on reference chromosome and chr.17p b) FISH on Chr. 17 (the green signal corresponds to the
centromere probe and the red signal to the p53 probe).
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Mutation state or IHC expression level weighted more
in decision making whenever one of the three parame-
ters was not available. Associations between p53 func-
tionality and the different variables are shown in Table 2.
In summary, the majority of tumors with a functional
p53 (78%) lacked TP53 mutations (p=0.01) and all
showed between 0-25% positive stained cells using im-
munohistochemistry (p<0.001). 78% of the tumors with
functional p53 had a near diploid DNA index raging
from 0.95-1.05 whereas 63% of the non functional p53
samples was highly aneuploid with DNA indexes ranging
1.41 – 1.95 (p<0.001). Samples with functional p53
showed significantly more retention of the p53 locus
(genotype AB) as compared to the group with either
aLOH (AAA/AAAA) (p=0.005), cnLOH (AA) (p<0.001)
and cases with multiclonallity (p=0.006). Moreover, the
frequency of functional p53 was increased in tumors
with LOH than with cnLOH (p=0.01). Furthermore, tu-
mors with a functional p53 were significantly overrepre-
sented in the group of right-sided tumors (p=0.035). Of
the tumors with non-functional p53, eighty-six percent
showed the MSS phenotype (p=0.009).
To corroborate the classification in functional and
non-functional p53 groups, we compared p53 targetgene expression levels between these two groups. We se-
lected genes for which expression was previously shown
to be p53 gene dosage dependent by Yoon et al. [22].
Eight genes differently expressed between both groups
were identified (Table 3). As expected, known p53 tar-
gets like MDM2 and CDKN1A were significantly higher
expressed in the p53 functional group than in the non
functional group (p=0.0025 and p=0.0013 respectively).
Genes higher expressed in the non functional group were
involved in many processes such as cell proliferation
(PRKCZ), protein ubiquitination (SIAH1), metabolism
(HMGCS1) and cell differentiation (PRKCZ, PDE6A).
Survival analysis
In a univariate survival analysis, p53 functionality was
prognostic; patients with functional p53 had a better can-
cer specific survival than patients with non-functional p53
(Log rank p=0.009) (Figure 3).
In our cohort, patients with MSI-H tumors are slightly
more frequent than expected from epidemiological stud-
ies (33% vs. 18% expected), nevertheless MMR status did
not influence survival (data not shown) nor the effects
of p53 functionality on survival.
Recently, the role of p53 and Csnk1a1 inactivation in
tumor invasiveness in mice has been demonstrated [3].
Table 2 Associations between clinicopathological variables and p53 functionality
p53 non functional N (%) p53 functional N (%) p value
TP53 mutational status
wt 7 (33) 14 (78) 0.01
mut 14 (67) 4 (22)
P53 IHC
0 3 (11) 7 (24) <0.001#
0 - ≤25% 1 (3) 22 (76)
>25% 24 (86) 0 (0)
Chr. 17 p status
AB 5 (18) 22 (76) <0.001*
LOH 2 (7) 4 (14)
Copy neutral LOH 9 (32) 0 (0)
Amplified LOH 5 (18) 1 (3)
Allelic Imbalance 1(4) 0 (0)
Two clones 6 (21) 2 (7)
Age category
50 – 59 4 (14) 6 (22) NS
60 – 69 10 (36) 9 (32)
70 – 79 10 (36) 9 (32)
80 – 89 4 (14) 4 (14)
DNA index
0.95 – 1.05 6 (22) 21 (78) <0.001¶
1.06 – 1.4 4 (15) 3 (11)
1.41 – 1.95 17 (63) 3 (11)
MMR status
MSI 4 (14) 14 (50) 0.009
MSS 24 (86) 14 (50)
Gender
Male 12 (43) 18 (62) NS
Female 16 (57) 11 (38)
Tumor Location
Right 10 (36) 19 (66) 0.035
Left 18 (64) 10 (34)
Stage
I and II 14 (50) 22 (76) 0.06
III 14 (50) 7 (24)
Median Follow up in months 66.75 89.77 0.4
*Χ2 test allelic status AB vs. LOH p=0.58; AB vs. CNLOH p<0.001; AB vs. ALOH p=0.005; AB vs. two clones p=0.006
LOH vs. CNLOH p=0.01; LOH vs. ALOH p=0.24; LOH vs. two clones p=0.28.
ALOH vs. CNLOH p=0.43; Amp LOH vs. two clones p=1.
CNLOH vs. two clones p=0.48.
# Χ2 test p53 IHC 0 vs. 0-25% p=0.07; 0 vs. >25% p<0.001; 0-25% vs. >25% p=0.001.
¶ Χ2 test DNA index 0.95 – 1.05 vs. 1.06 – 1.4 p=0.16; 0.95 – 1.05 vs. 1.41- 1.95 p<0.001; 1.06 – 1.40 vs. 1.41 – 1.95 p=0.29.
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modulate p53 effects in disease outcome. Patients were di-
vided according to the expression level. In the group with
high CSNK1A1 expression the expression level of thethree probes analyzed (A_23_P213551; A_24_P183292;
A_24_P251899) exceeded the median value for that spe-
cific probe while in cases with low CNSK1A1 expression
the value was lower than the median.













LMO3 12p12.3 Lim domain only 3 (rhombotin like 2). Expression of LMO-3 represses p53 mediated mRNA
expression of target genes.
1.2E-02
↑non functional
CDKN1A 6p21.2 Cyclin dependent kinase inhibitor. Causes cell cycle arrest in the presence of DNA damage. 1.3E-02↑functional
PDE6A 5q31.2-
q34
Phosphodiesterase 6A, cGMP-specific, rod, alpha 7.47E-02
↑non functional
SIAH1 16q12 Seven in absentia homolog 1. Involved in ubiquitination and proteosome related









MDM2 p53 binding protein homolog (Mouse) 1.25E-02
↑ functional
HMGCS1 5p14-p13 3-hydroxy 3-methylglutaryl-CoA synthase I 1E-01
↑functional
All p-values are corrected for multiple tests.
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with each other (Pearson’s correlation coefficient =0.94
p<0.001 between A_23_P213551 and A_24_P251899,
0.747 p<0.001 between A_23_P213551 and A_24_P183292
and finally 0.743 p<0.001 between A_24_P183292 and
A_24_P251899) (Figure 4). The three probes had the same
detrimental effect on survival in a univariate analysis with
different significant p values (data not shown). We se-
lected the probe (A_24_P183292) with the most significant
results (Log rank p=0.003) for further analyses.
CSNK1A1 expression significantly altered the effect of
p53 in survival as shown in Figure 5. CSNK1A1 had noFigure 3 Kaplan Meier plots for CSS according to p53 functionality.influence on survival when p53 is functional, however,
when p53 was non-functional, CSNK1A1 expression
influenced disease outcome dramatically. Patients with
low CSNK1A1 expression had a very poor prognosis com-
pared with patients with high CSNK1A1 expression (Log
rank p=0.007) (Figure 5).
Subsequently, we compared the patients with non func-
tional p53 and low CSNK1A1 expression with the rest of
patients (i.e. non functional p53 and high CSNK1A1
expression or functional p53 with high or low CSNK1A1
expression). Survival in patients with both genes affected
was decreased compared to patients with one of both
Figure 4 Trends in expression of the three CSNK1A1 probes.
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detrimental effect on disease outcome was significant in a
multivariate model including tumor stage, gender, tumor
ocation and MMR status in the model (HR=4.74 95% CI
1.47-15.34 p=0.009) (Table 4).
Expression of invasiveness genes
Elyada et al. reported up regulation of eight genes
in p53 and Csnk1a1 double knockout mice and their
involvement in murine tumor invasiveness [3]. We
analysed their expression in our series. Two genes,Figure 5 Kaplan Meier plots for CSS according to CSNK1A1 expressionmainly PLAT (plasminogen activator tissue) and
PNLPRP1 (pancreatic lipase related protein 1) were
significantly differently expressed between the two
groups of patients; the group with low CSKN1A1
expression and non-functional p53 vs. the remaining
group (with functional p53 and high or low CSKN1A1
expression and non functional p53 and high CSNK1A1
expression). PLAT was upregulated in the latter group
(p=0.009) whereas PNLPRP1 was higher expressed in
the non-functional p53 and low CSNK1A1 expression
(p=0.009).stratified on the base of p53 functionality.
Figure 6 Kaplan Meier for CSS according to p53 and CSNK1A1 combination variable.
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TP53 is a transcription factor with important functions
in cellular apoptosis, senescence, DNA damage repair,
autophagy, aging and glycolysis [34-36]. Therefore, it is a
strategic target for inactivation in cancer cells; indeed,
somatic mutations are found in approximately 50% of
all tumors [4]. However, the consequences of p53Table 4 Cox Proportional Hazards Model: multivariate surviva
Variables HR
p53 & CSNK1A1
p53 - & CSNK1A1 + and p53+ & CSNKA1A +/− Refer
p53 - CSNK1A1 - 4.7
Tumor stage











* Statistically significant results.inactivation in disease outcome in colon cancer remain
controversial and subject to discussion. These inconclu-
sive result could in part be explained by the combination
of differences in the techniques used to assess p53 alter-
ations (IHC or mutation analysis), and the many possible
ways of p53 inactivation (deletion and dominant nega-
tive, loss or gain of function mutations).l analysis
95% CI p value
ent
4 1.47 – 15.34 0.009*
ent
8 1.08 – 11.2 0.037*
ent
0.32 – 2.67 0.58
0.32 – 2.97 0.88
ent
0.097 – 1.91 0.27
ent
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determined tumor ploidy and TP53 locus allelic state.
Next, we assessed TP53mutation state and protein expres-
sion by IHC. By integrating these data we could predict
p53 functionality. The classification in functional and non-
functional p53 was supported by the significant differences
in target gene expression between these two groups. Thus,
with this approach complete information on the gene was
obtained allowing a more reliable classification than solely
by mutation analysis or immunohistochemistry.
As it could be expected based on the functions of p53,
tumors with a non-functional p53 were highly aneuploid.
Moreover, the prognosis for patients with these tumors
was worse compared to the group with functional p53.
We have also shown that p53 can indeed behave as a
haploinsufficient tumor suppressor gene as demonstrated
in mouse models [20]. We accurately assessed the TP53
genotypes by combining the allelic state at the TP53 locus
using SNP arrays, combined with TP53 mutation analyses.
In our cohort there were a few cases with LOH at the
TP53 locus but without mutations in exons 5, 6, 7 and 8
and without positive immunostaining. Moreover, the tu-
mors had a near-diploid genome and were associated with
a good disease outcome as compared with other patients
(Supplementary data figure 1). Our finding supports the
observation that p53 +/− mice did develop tumors but
show a milder phenotype than p53−/− mice [20].
Recently, in mice Csnk1a1 or CKIα expression has
been implicated in colon cancer invasiveness and cell
transformation in the gut [3]. CSNK1A1 is a serine/
threonine kinase that phosphorylates β-catenin to target
it for destruction [37]. In a mouse model, ablation of
Csnk1a1 caused the accumulation of β-catenin in the
cytoplasm and nucleus activating many Wnt target genes
although no tumor formation was observed. Instead,
senescence was induced in these cells pointing to a pos-
sible role of p53 in tumor inhibition. Indeed, the authors
found that inactivation of both Csnk1a1 and p53 rendered
the cell malignant and rapidly invasive [3]. Likewise, in the
present cohort of patients, we have identified CSNK1A1
as a dramatic modifier of p53 effects on survival. High
CSNK1A1 expression partly counteracts the negative ef-
fects of a non functional p53. Accordingly, low CSNK1A1
expression and non functional p53 was equal to a very
poor prognosis with a median survival time of 3 years and
a 5-year survival of only 35%, which is extremely poor for
early stage disease. Furthermore, this negative effect on
survival was independent of disease stage, gender, tumor
location and mismatch repair state, as shown in the multi-
variate analysis.
The exact mechanism behind this poor survival is un-
known; Elyada et al. showed that expression of certain
genes was upregulated in the double knockout mice
(p53−/− and Csnk1a1−/−) as compared with the onlyCsnk1a1−/− mice. Some of these genes were involved in
loss of enterocyte polarity, tissue remodeling and cell
motility; all functions likely to be involved in tumor in-
vasiveness [3]. In the present cohort of patients only two
of the human homologues from the murine gene list
proposed were differentially expressed, i.e. plasminogen
activator tissue (PLAT) and pancreatic lipase related
protein 1 (PNLRP1) in tumors with impaired p53 func-
tion and low expression of CSNK1A1 versus the
remaining tumors. The latter results might reflect differ-
ences between mouse and man. Moreover, the human
comparison was not identical to the murine comparison
by Elyada and co workers. Furthermore in contrast to
the murine model, PLAT was upregulated in the group
with at least one active gene (functional p53 with low or
high CSNK1A1 expression and non functional p53 with
high CSNK1A1 expression) and could therefore be asso-
ciated with a better survival. In human, the increased
expression of the plasminogen activator inhibitor was as-
sociated with the occurrence of distant metastasis in
colon cancer [38], probably leading to decreased levels
of PLAT which would corroborate our findings. To our
knowledge, the role of PNLRP1 in tumor invasiveness
and progression is so far unknown.
Conclusion
The combination of several approaches provides add-
itional and accurate information on p53 status showing a
detrimental effect on survival when p53 function is im-
paired. Nevertheless, gene interplay remains very import-
ant in tumor biology as it is illustrated by the modifying
role of CSNK1A1 gene expression on the survival effects
of TP53 in colon cancer. Loss of both genes confers an ex-
tremely poor prognosis to colon cancer patients.
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